Novus Therapeutics, a clinical stage biotechnology company, completed the acquisition of Anelixis Therapeutics, a privately held clinical stage biotechnology company. Financial terms were not disclosed. "We are excited about AT-1501 and the potential to develop and commercialize the next generation anti-CD40L antibody, a well-validated target with broad therapeutic possibilities. After exploring a range of strategic options to maximize shareholder value, we believe this acquisition represents the greatest value creation opportunity for Novus stockholders, and we are confident that we have the management and scientific leadership team to fully realize this opportunity for patients in need of new treatment options," Keith A. Katkin, Novus Chairman of the Board of Directors.